[
  {
    "title": "3 Pharma Stocks That Are Money-Printing Machines in 2024",
    "published": 1713217891,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors",
    "published": 1713217820,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions",
    "published": 1713189617,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?",
    "published": 1713187800,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "Market Whales and Their Recent Bets on BMY Options",
    "published": 1713184680,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "How To Invest $100,000 Today With Peace Of Mind",
    "published": 1712998800,
    "posting_price": 46.59405469,
    "close_price": 46.73857498,
    "percent_change": 0.31016895
  },
  {
    "title": "Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY",
    "published": 1712933169,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals",
    "published": 1712928120,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)",
    "published": 1712923590,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024",
    "published": 1712919600,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Healthpeak Properties: A Quality Healthcare REIT That Should Get Back To Dividend Growth",
    "published": 1712905200,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map",
    "published": 1712898708,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF)",
    "published": 1712898060,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio",
    "published": 1712895960,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom",
    "published": 1712884980,
    "posting_price": 47.24922094,
    "close_price": 46.51697159,
    "percent_change": -1.54975963
  },
  {
    "title": "If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names",
    "published": 1712857753,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study",
    "published": 1712842200,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "Building a Better Future: Bristol Myers Squibb 2023 ESG Report",
    "published": 1712841000,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "A Closer Look At Bristol-Myers Squibb Company's (NYSE:BMY) Impressive ROE",
    "published": 1712833227,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "May 31st Options Now Available For Bristol Myers Squibb (BMY)",
    "published": 1712828580,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today",
    "published": 1712825520,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "This Is What Whales Are Betting On Bristol-Myers Squibb",
    "published": 1712807400,
    "posting_price": 48.6173655,
    "close_price": 47.32629776,
    "percent_change": -2.65556911
  },
  {
    "title": "Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News",
    "published": 1712769540,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "The Pharmaceutical Industry Finds Itself At A Historical Crossroads",
    "published": 1712767671,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist",
    "published": 1712743440,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data",
    "published": 1712711940,
    "posting_price": 49.1761876,
    "close_price": 48.45357513,
    "percent_change": -1.46943573
  },
  {
    "title": "Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing",
    "published": 1712699419,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data",
    "published": 1712683620,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers: cancer treatment results",
    "published": 1712656359,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade",
    "published": 1712650860,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Upcoming Catalysts Position Perrigo For Sustained Long-Term Dividend Growth",
    "published": 1712641773,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol-Myers Squibb snaps a six day losing spell",
    "published": 1712632980,
    "posting_price": 49.26290174,
    "close_price": 49.71573639,
    "percent_change": 0.91922042
  },
  {
    "title": "Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation",
    "published": 1712606451,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma",
    "published": 1712597220,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)",
    "published": 1712590200,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "IN BRIEF: Bristol-Myers unveils positive data on cancer drug adagrasib",
    "published": 1712588220,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma",
    "published": 1712583600,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers releases encouraging data for Krazati in colorectal cancer",
    "published": 1712574300,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals",
    "published": 1712574000,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers reports positive Phase 3 data for schizophrenia drug",
    "published": 1712572920,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers: Krazati plus cetuximab showed ORR of 34%, PFS of 6.9 months",
    "published": 1712572440,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics",
    "published": 1712568780,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy",
    "published": 1712561309,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers: new data on schizophrenia",
    "published": 1712551965,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol-Myers Squibb\u2019s Hold Rating: Balancing KarXT\u2019s Efficacy and Safety with Financial Uncertainties",
    "published": 1712551680,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "DGI For The DIY: 2023 Dividend Portfolio Review",
    "published": 1712546542,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol-Myers Squibb treatment improves schizophrenia symptoms in test",
    "published": 1712546340,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stocks",
    "published": 1712493540,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Morgan Stanley sees Fed rate cut fueling biotech stock performance",
    "published": 1712493180,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Possible Bearish Signals With Bristol-Myers Squibb Insiders Disposing Stock",
    "published": 1712487669,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",
    "published": 1712473500,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion",
    "published": 1712471400,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers presents new data from Phase 3 EMERGENT program evaluating KarXT",
    "published": 1712468640,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers presents new interim long-term efficacy data from EMERGENT-4 trial",
    "published": 1712468100,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society",
    "published": 1712423700,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies",
    "published": 1712423700,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society",
    "published": 1712423700,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "5 Relatively Secure And Cheap Dividend Stocks To Invest In - April 2024",
    "published": 1712395800,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Johnson & Johnson wins FDA nod for Carvykti label expansion",
    "published": 1712389260,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "Bristol Myers highlights safety of KarXT schizophrenia therapy",
    "published": 1712370240,
    "posting_price": 49.40742081,
    "close_price": 49.23399353,
    "percent_change": -0.35101464
  },
  {
    "title": "The 3 Most Undervalued Biotech Stocks to Buy in April 2024",
    "published": 1712339647,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "IN BRIEF: Bristol-Myers secures US FDA approval for Abecma",
    "published": 1712323800,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "UPDATE 2-US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer",
    "published": 1712323301,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "U.S. FDA Approves Bristol Myers Squibb and 2seventy bio\u2019s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy",
    "published": 1712322300,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer",
    "published": 1712321040,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use",
    "published": 1712316300,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Bristol Myers: FDA approves Abecma in multiple myeloma",
    "published": 1712309515,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer",
    "published": 1712308901,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Biggest stock mover today: GCTS, TSVT, GRIN, ANGO, ATUS, and more",
    "published": 1712308620,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "U.S. FDA allows expanded use of Bristol Myers' cell therapy",
    "published": 1712308144,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Bristol Myers, 2seventy bio receive FDA approval for Abecma to treat multiple myeloma",
    "published": 1712306280,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Bristol Myers, 2seventy Bio's Abecma approved by U.S. FDA",
    "published": 1712304540,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "published": 1712288700,
    "posting_price": 49.32071095,
    "close_price": 49.44596481,
    "percent_change": 0.25395794
  },
  {
    "title": "Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More",
    "published": 1712251260,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know",
    "published": 1712235614,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "Merck puts KRAS cancer drug competitor to the test",
    "published": 1712230680,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "Top buy-rated stocks and sell-rated stocks within Health Care - Citi",
    "published": 1712225880,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "May 24th Options Now Available For Bristol Myers Squibb (BMY)",
    "published": 1712223360,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.",
    "published": 1712206800,
    "posting_price": 50.04331894,
    "close_price": 49.52304077,
    "percent_change": -1.0396556
  },
  {
    "title": "Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion",
    "published": 1712150040,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers wins label expansion for anemia therapy in EU",
    "published": 1712146200,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 20% if they invested a year ago",
    "published": 1712145637,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol-Myers Squibb Co's Dividend Analysis",
    "published": 1712142155,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers: European Commission expands approval of Reblozyl",
    "published": 1712120220,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers: EU approval extended for Reblozyl",
    "published": 1712119372,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY)",
    "published": 1712117820,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Standard BioTools announces multi-year agreement with Bristol Myers",
    "published": 1712113380,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "European Commission Expands Approval of Bristol Myers Squibb\u2019s Reblozyl\u00ae (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)",
    "published": 1712102880,
    "posting_price": 50.23933864,
    "close_price": 49.69646835,
    "percent_change": -1.08056815
  },
  {
    "title": "Bristol Myers Squibb (BMY) Stock Moves -0.47%: What You Should Know",
    "published": 1712094619,
    "posting_price": 50.57268286,
    "close_price": 50.22982025,
    "percent_change": -0.6779601
  },
  {
    "title": "Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals",
    "published": 1712082600,
    "posting_price": 50.57268286,
    "close_price": 50.22982025,
    "percent_change": -0.6779601
  },
  {
    "title": "Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts",
    "published": 1712056740,
    "posting_price": 50.57268286,
    "close_price": 50.22982025,
    "percent_change": -0.6779601
  },
  {
    "title": "Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint",
    "published": 1712049693,
    "posting_price": 50.57268286,
    "close_price": 50.22982025,
    "percent_change": -0.6779601
  },
  {
    "title": "Ex-Dividend Reminder: Bristol Myers Squibb, Preferred Bank and Kite Realty Group Trust",
    "published": 1712049420,
    "posting_price": 50.57268286,
    "close_price": 50.22982025,
    "percent_change": -0.6779601
  },
  {
    "title": "Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript",
    "published": 1714487810,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It",
    "published": 1714482015,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "Stifel, Morgan Stanley bullish on newly public Contineum",
    "published": 1714479300,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "A Closer Look at Bristol-Myers Squibb's Options Market Dynamics",
    "published": 1714473480,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "BMY July 19th Options Begin Trading",
    "published": 1714469700,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "FTC expands patent listing challenges for drugs",
    "published": 1714468440,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations",
    "published": 1714467180,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "Bristol Myers Squibb: Tough Times Continue",
    "published": 1714454958,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb",
    "published": 1714453200,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Bristol-Myers Squibb (BMY) and Laboratory (LH)",
    "published": 1714443660,
    "posting_price": 42.77865813,
    "close_price": 42.33545303,
    "percent_change": -1.03604255
  },
  {
    "title": "J&J, Bristol Myers lose challenges to US drug price negotiation program",
    "published": 1714427556,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "AbbVie: The Inevitable Is Happening",
    "published": 1714403333,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week",
    "published": 1714395360,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "How Is The Market Feeling About Bristol-Myers Squibb?",
    "published": 1714387860,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Repertoire\u00ae Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases",
    "published": 1714384800,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript",
    "published": 1714381596,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Immatics N.V.: An Intriguing Developmental Concern",
    "published": 1714380690,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)",
    "published": 1714371540,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Bristol Myers, Repertoire to develop tolerizing vaccines in multi-year pact",
    "published": 1714370520,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Repertoire pivot pays dividends with Bristol Myers deal",
    "published": 1714370400,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Bristol Myers enters multi-year strategic collaboration with Repertoire",
    "published": 1714368360,
    "posting_price": 43.44345971,
    "close_price": 43.00989151,
    "percent_change": -0.99800569
  },
  {
    "title": "Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)",
    "published": 1714282380,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags",
    "published": 1714225726,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "Dividend Champion, Contender, And Challenger Highlights: Week Of April 28",
    "published": 1714210198,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "2 Very Cheap Turnarounds Yielding Up To 7%",
    "published": 1714205700,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "Wall Street Breakfast: What Moved Markets",
    "published": 1714196400,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "Amgen\u2019s Blincyto data send Cullinan higher",
    "published": 1714185660,
    "posting_price": 43.44346356,
    "close_price": 43.00989532,
    "percent_change": -0.99800569
  },
  {
    "title": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals",
    "published": 1714134300,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb\u2019s Opdivo\u00ae (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma",
    "published": 1714129140,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers: positive opinion from the CHMP for Opdivo",
    "published": 1714121254,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers price target lowered by $5 at BofA, here's why",
    "published": 1714120140,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer",
    "published": 1714120106,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "GLOBAL BROKER RATINGS: Stifel cuts Caterpillar; HSBC likes Ashtead",
    "published": 1714116780,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)",
    "published": 1714113660,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers announces EMA's CHMP recommended approval of Opdivo",
    "published": 1714111380,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)",
    "published": 1714108119,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)",
    "published": 1714105560,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns",
    "published": 1714105200,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers price target lowered by $8 at Barclays, here's why",
    "published": 1714104360,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY)",
    "published": 1714103280,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Q1 2024 Bristol-Myers Squibb Co Earnings Call",
    "published": 1714099150,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points",
    "published": 1714097040,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol, Sanofi, Takeda gain positive CHMP recommendations",
    "published": 1714095360,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol-Myers Squibb Co (BMY) Q1 2024 Earnings Call Transcript Highlights: Navigating ...",
    "published": 1714093380,
    "posting_price": 43.04843646,
    "close_price": 43.21222687,
    "percent_change": 0.38047935
  },
  {
    "title": "Bristol Myers Squibb stock tumbles on cost-cutting initiative",
    "published": 1714077698,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge",
    "published": 1714055433,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX",
    "published": 1714069680,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions",
    "published": 1714069419,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)",
    "published": 1714067356,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "NEW YORK MARKET CLOSE: Stocks ebb on stagflation fears as growth slows",
    "published": 1714061580,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall",
    "published": 1714061319,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)",
    "published": 1714060680,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Why Bristol Myers Squibb Stock Is Sinking Today",
    "published": 1714060654,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off",
    "published": 1714060609,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat",
    "published": 1714060080,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma",
    "published": 1714059724,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort",
    "published": 1714052940,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript",
    "published": 1714059011,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts",
    "published": 1714056840,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Is Bristol Myers Squibb Stock a Millionaire Maker?",
    "published": 1714056300,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "published": 1714051800,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb Co (BMY) Q1 2024 Earnings Report: A Detailed Overview",
    "published": 1714050743,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myer Squibb Company (BMY) Q1 2024 Earnings Call Transcript",
    "published": 1714050666,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Massive Job Cuts Send Bristol-Myers Squibb (NYSE:BMY) into Tailspin",
    "published": 1714047480,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "UPDATE 2-Bristol Myers posts quarterly loss, revenue rises 5%",
    "published": 1714045504,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Massive Job Cuts Send Bristol-Myers Squibb (NYSE:BMY) Stock Into Tailspin",
    "published": 1714044900,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "What You Missed On Wall Street This Morning",
    "published": 1714043400,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal",
    "published": 1714043220,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving plan",
    "published": 1714042922,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb Reports First Quarter Financial Results for 2024",
    "published": 1714042740,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers posts quarterly loss, revenue rises 5%",
    "published": 1714042740,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024",
    "published": 1714042560,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts",
    "published": 1714042260,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Trending : Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts",
    "published": 1714041571,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb Co. Becomes Oversold",
    "published": 1714041120,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers to cut 6% of workforce, trim drug pipeline",
    "published": 1714039860,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers to cut 2,200 jobs as part of $1.5B cost savings plan",
    "published": 1714036800,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers to cut 2,200 jobs as part of $1.5B cost saving plan",
    "published": 1714036500,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Shedding 2,200 Jobs in Cost Savings Push",
    "published": 1714035140,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers: heavy quarterly loss on charges",
    "published": 1714032519,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Cuts '24 EPS View, Posts Narrower-Than-Seen 1Q Loss",
    "published": 1714031611,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "TOP NEWS: Bristol-Myers beats on revenue but swings to quarterly loss",
    "published": 1714031580,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Fly Intel: Pre-market Movers",
    "published": 1714031580,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb : Q1 2024 Results Presentation (with Appendix)",
    "published": 1714030989,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers Squibb shares fall amid sluggish sales of some newer drugs",
    "published": 1714029300,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers: Q1 Earnings Snapshot",
    "published": 1714029150,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb Q1 Earnings Call Strategy Insights",
    "published": 1714028580,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers posts Q1 beat despite growth headwinds",
    "published": 1714028460,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers in charts: Revenue from Eliquis rises, while Opdivo drops in Q1",
    "published": 1714027800,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Purple Biotech's Phase 2 pancreatic cancer study selected as presentation",
    "published": 1714026780,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers lowers FY24 adjusted EPS view to 40c-70c, consensus 65c",
    "published": 1714025100,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb Company\u00a0 Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M",
    "published": 1714024980,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol Myers reports Q1 adjusted EPS ($4.40), consensus ($4.44)",
    "published": 1714024980,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst",
    "published": 1714022580,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "PureTech Announces Annual Results for Year Ended December 31, 2023",
    "published": 1714022520,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates",
    "published": 1714019760,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "What You Missed On Wall Street On Thursday",
    "published": 1714015800,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results",
    "published": 1714008900,
    "posting_price": 45.65947194,
    "close_price": 43.06770325,
    "percent_change": -5.67630018
  },
  {
    "title": "Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?",
    "published": 1713974700,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?",
    "published": 1713964740,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "See Which Of The Latest 13F Filers Holds Bristol Myers Squibb",
    "published": 1713963420,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "Bristol Myers Squibb : Preliminary Q1 2024 Acquired IPRD and Licensing Income Schedule",
    "published": 1713950711,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "Bristol-Myers Earnings Preview: Major near-term headwinds invites worries about Q1 results",
    "published": 1713948300,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "Notable companies reporting before tomorrow's open",
    "published": 1713943500,
    "posting_price": 47.21068129,
    "close_price": 47.07579422,
    "percent_change": -0.28571303
  },
  {
    "title": "NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
    "published": 1713880859,
    "posting_price": 47.36484021,
    "close_price": 47.2010498,
    "percent_change": -0.3458059
  },
  {
    "title": "Former Bristol Myers CEO tapped as Novartis\u2019 next board chair",
    "published": 1713873720,
    "posting_price": 47.36484021,
    "close_price": 47.2010498,
    "percent_change": -0.3458059
  },
  {
    "title": "S&P 500 stocks with biggest estimated EPS declines for Q1",
    "published": 1713872400,
    "posting_price": 47.36484021,
    "close_price": 47.2010498,
    "percent_change": -0.3458059
  },
  {
    "title": "Baron Health Care Fund Q1 2024 Shareholder Letter",
    "published": 1713864600,
    "posting_price": 47.36484021,
    "close_price": 47.2010498,
    "percent_change": -0.3458059
  },
  {
    "title": "Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?",
    "published": 1713862803,
    "posting_price": 47.36484021,
    "close_price": 47.2010498,
    "percent_change": -0.3458059
  },
  {
    "title": "Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know",
    "published": 1713808560,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol-Myers inks USD380 million supply agreement with Cellares",
    "published": 1713797040,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics",
    "published": 1713791771,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers taps startup to boost cell therapy production",
    "published": 1713785400,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster",
    "published": 1713783540,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Is Bristol Myers Squibb A Buy At These Bottom Levels?",
    "published": 1713778200,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal",
    "published": 1713776880,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers, Cellares ink $380M CAR-T therapies supply deal",
    "published": 1713776100,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers signs $380 mln CAR-T therapies supply deal with Cellares",
    "published": 1713771835,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers signs supply agreement with Cellares",
    "published": 1713770822,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies",
    "published": 1713769604,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "5 Crash-Proof Stocks to Buy Immediately",
    "published": 1713769440,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers price target lowered by $3 at Cantor Fitzgerald, here's why",
    "published": 1713766680,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Bristol Myers and Cellares sign $380M agreement for CAR T cell therapies",
    "published": 1713765780,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Options Volatility and Implied Earnings Moves This Week, April 22 \u2013 April 26, 2024",
    "published": 1713765720,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "SCHD: If You've Won The Game, Take A Little Off The Top",
    "published": 1713746499,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Is Bristol-Myers Squibb (NYSE:BMY) Using Too Much Debt?",
    "published": 1713700822,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "High-Quality Dividend Growth Near 52-Week Lows: Apple Is Attractive",
    "published": 1713692167,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",
    "published": 1713683100,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week",
    "published": 1713674940,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Goldman picks top capex and R&D stocks",
    "published": 1713663840,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "THQ: Collecting A High Yield From Increased Medical Spending",
    "published": 1713614580,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations",
    "published": 1713604980,
    "posting_price": 47.21067873,
    "close_price": 47.3455658,
    "percent_change": 0.28571305
  },
  {
    "title": "Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout",
    "published": 1713534583,
    "posting_price": 46.44952892,
    "close_price": 47.14323807,
    "percent_change": 1.49346864
  },
  {
    "title": "Got $500? 3 Healthcare Stocks to Buy and Hold Forever",
    "published": 1713528900,
    "posting_price": 46.44952892,
    "close_price": 47.14323807,
    "percent_change": 1.49346864
  },
  {
    "title": "FDA Mandates \"Boxed Warning\" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies",
    "published": 1713515400,
    "posting_price": 46.44952892,
    "close_price": 47.14323807,
    "percent_change": 1.49346864
  },
  {
    "title": "FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk",
    "published": 1713503640,
    "posting_price": 46.44952892,
    "close_price": 47.14323807,
    "percent_change": 1.49346864
  },
  {
    "title": "These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?",
    "published": 1713490380,
    "posting_price": 46.44952892,
    "close_price": 47.14323807,
    "percent_change": 1.49346864
  },
  {
    "title": "Earnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline",
    "published": 1713448904,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "Interesting BMY Put And Call Options For December 20th",
    "published": 1713433080,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "Johnson & Johnson: Buy This Bargain Before It's Gone",
    "published": 1713425319,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "AbbVie buyout Cerevel posts late-stage win for Parkinson\u2019s disease drug",
    "published": 1713420360,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "Bristol Myers price target raised by $1 at Wells Fargo, here's why",
    "published": 1713417540,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)",
    "published": 1713417060,
    "posting_price": 46.17975564,
    "close_price": 46.53624344,
    "percent_change": 0.77195688
  },
  {
    "title": "3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500",
    "published": 1713381639,
    "posting_price": 46.67112897,
    "close_price": 46.09304047,
    "percent_change": -1.23864263
  },
  {
    "title": "2 High-Yield Dividend Stocks to Buy and Hold for 10 Years",
    "published": 1713360600,
    "posting_price": 46.67112897,
    "close_price": 46.09304047,
    "percent_change": -1.23864263
  },
  {
    "title": "Bristol-Myers Squibb: Market Pessimism Won't Last Forever",
    "published": 1713353443,
    "posting_price": 46.67112897,
    "close_price": 46.09304047,
    "percent_change": -1.23864263
  },
  {
    "title": "Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors",
    "published": 1713325680,
    "posting_price": 46.67112897,
    "close_price": 46.09304047,
    "percent_change": -1.23864263
  },
  {
    "title": "As more rare disease therapies launch, their prices are rising",
    "published": 1713266880,
    "posting_price": 46.68076774,
    "close_price": 46.49770355,
    "percent_change": -0.39216191
  },
  {
    "title": "Pfizer's Doldrums, Just A Bad Case Of COVID-19?",
    "published": 1713258950,
    "posting_price": 46.68076774,
    "close_price": 46.49770355,
    "percent_change": -0.39216191
  },
  {
    "title": "GE Aerospace Takes Center Stage in T. Rowe Price Equity Income Fund's Q1 Portfolio Adjustments",
    "published": 1713240120,
    "posting_price": 46.68076774,
    "close_price": 46.49770355,
    "percent_change": -0.39216191
  }
]